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I. Smoking and Tobacco Use Prevalence in Developed and  
Developing Nations 
Tobacco use among women is undergoing dynamic and rapid shifts 
throughout the world. It is estimated that 250 million women (11% of 
women worldwide), compared to almost 1 billion men, in the world are 
daily smokers: 22% in developed nations vs. 9% in developing nations 
(compared to 35% of men vs. 50% of men, respectively). Oral tobacco 
use is far more prevalent in South Asia, and may be as high as 30% in 
women, compared to 25% in men. In many developed nations, notably 
the USA, Canada, the UK and Australia, smoking among women con-
tinues to slowly decline, but in several European countries (southern, 
central and eastern) there has not been a decline and smoking may even 
be increasing. From 1960-2004, smoking prevalence has remained rela-
tively stable in Japan (15%-17%); in the UK, it decreased from 42% 
to 24%; and in the USA it decreased from 34% to 19%. The top ten 
countries with the highest reported smoking rates among women (2005 
or latest available data) are: Cook Islands (71%), Nauru (59%), Guinea 
(47%), Chile (37%), Serbia & Montenegro (34%), Kiribati, FYR 
Macedonia (32%), Lebanon, Tuvalu (31%), and Boznia & Herzegovina 
(30%). The comparison top 10 countries for men are: Yemen (77%), 
Djibouti (75%), Cambodia, China (67%), Kazakhstan, Rep. Korea 
(65%), Armenia (62%), Albania, Russian Federation, Samoa (60%), 
and Guinea (59%).1
Unfortunately, tobacco use among girls is rising worldwide; there were 
no gender differences in smoking among half of the countries surveyed 
in the Global Youth Tobacco Survey, and girls have higher smoking 
rates than boys in some parts of Europe (e.g., Austria, Czech Republic, 
Portugal, Spain, Sweden, Norway) and South America (e.g., Argenti-
na). Factors increasing girls smoking are similar in both sexes: industry 
marketing, easy access, affordability, peer smoking and inﬂuence, 
parental modeling and normative behavior. Both girls and boys still be-
lieve that smoking enhances one’s image and increases popularity; and 
girls smoke to control weight. In many countries, smoking still appears 
in movies, magazines, on billboards and other media targeted to youth 
conveying positive social, physical and style images. Broader buying 
power, women’s emancipation and relaxation of cultural strictures are 
other factors associated with greater female smoking.1 
II. Major Biobehavioral Variables in Women’s Smoking & Tobacco 
Use: Biological Determinants and Social Factors
Among the biological variables determining women’s smoking behav-
ior, nicotine dependence has been most thoroughly explored. Perkins2 
has been the major proponent of the view that women ﬁnd nicotine less 
reinforcing than men and are more responsive to smoking cues, but this 
hypothesis has not been supported by pharmacologic trials that show 
women to be equally responsive to NRT and bupropion (see below). 
There may be gender-speciﬁc genetic variation in nicotine dependence 
among subgroups of women,3 which might account for women with 
greater nicotine dependence having less success in cessation. Depres-
sion and negative affect in general have been considered of greater im-
portance in controlling women’s smoking behavior as well as a number 
of other factors including weight maintenance or loss, and the role of 
hormonal and menstrual factors.4 Pregnancy is considered a “teachable 
moment” for smoking cessation, when many women quit spontane-
ously. However relapse is still very high after childbirth, and successful 
interventions to promote abstinence during childrearing are still much 
needed. Among the social and societal factors affecting smoking, peer 
inﬂuence and norms, parental behavior and approval, perceived risks, 
attitudes and beliefs about smoking, the inﬂuence of media, marketing 
and policy initiatives remain very important, even more in the develop-
ing than in the developed nations.
III. Smoking Cessation
Studies on smoking cessation have largely been conducted in the devel-
oped world. There is a dearth of information on needs assessment and 
cessation in the developing nations.
A. Population-based vs. clinical data: do women have lower quit rates 
than men? 
There is no consistent agreement on whether women have greater dif-
ﬁculty stopping smoking than men. In the USA, population data do not 
demonstrate meaningful gender differences in the percentage of women 
and men current smokers who want to quit (72.2% F vs 68.0%M), and 
who quit for more than one day (41.9%F vs. 40.2%M).5 It has been 
hypothesized that population surveys favoring males over females in 
cessation rates could be accounted for by men switching from ciga-
rettes to other forms of tobacco, such as cigars or snus. Analysis of 
California population prevalence data regarding smoking cessation 
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with and without assistance, in 1996, showed that women were more 
likely to use all methods of assistance (counseling, nicotine replace-
ment [NRT], counseling + NRT) than men (22.1% vs. 18.3%) and that 
usage increased with age. Use of assistance was also associated with 
higher long term (12 month) quit rate across gender (15.2% vs. 7.0%).6 
In formal cessation programs some studies do show men having higher 
quit rates than women. For example, Wetter et al7 examined 3 RCTs of 
nicotine patch treatment (N=632). Men had higher abstinence rates than 
women at all follow-ups. Multiple mediators were examined but none 
accounted for the gender difference (demographics, smoking history, 
pre-cessation affect/depression, smoking outcome expectations, coping 
style, health symptoms, post-cessation withdrawal/affect/stress). Killen 
et al8 analyzed the data from 4 trials encompassing 13 studies, with 
a total of 2086 participants. Quit rates were not signiﬁcantly different 
for men and women. Gender was not a moderator within subgroups 
matched for established moderators, such as nicotine dependence. 
These authors state that their analyses generalize to formal intervention 
programs, including physician advice, with less intensive behavioral 
components (short of individual or group counseling), but perhaps not 
to studies of (population-based) spontaneous cessation. Interestingly, 
Swan et al9 identiﬁed wide heterogeneity among men and women in 
a large randomized controlled trial (RCT) of bupropion and counsel-
ing, which involved 875 F and 649M). Heterogeneity was greater 
in women, but women also had a subgroup with the highest rate of 
quitting (42% at 12 months). This group was characterized by higher 
education, longer quit attempts, low levels of stress, higher adherence 
to medication, and the lowest dropout from medication. The group of 
women with the lowest quit rate (9.8% at 12 months) was characterized 
by high BMI, low prior quit rates, low adherence to medication and 
greater likelihood of discontinuing medication. Overall, the rate of non-
smoking among women (27.5%) was lower than among men (32.8%, p. 
<0.04). There was no treatment X individual characteristics interaction. 
The authors recommend tailoring interventions to subgroups at highest 
risk of relapse. In another study,10 a RCT of a group program followed 
by basic support vs. enhanced (tailored and targeted) telephone coun-
seling, there was a signiﬁcant treatment X gender interaction. In the 
enhanced group, men had higher quit rates through 15 month follow-up 
and lower relapse; women fared better in the basic support condition 
and did more poorly in rate of relapse. However, women did not have 
a lower success rate overall or a higher relapse rate; in fact, there was a 
trend for superior quitting. History of depression did not interact with 
condition. Several studies below, using pharmacotherapy, found gender 
differences favoring men, in smoking cessation. although not interact-
ing with drug treatment. Thus, these studies produce a variety of sug-
gestive ﬁndings and stimulus for further research but no clear outcome 
on gender differences in success in quitting and remaining abstinent.
B. Do men and women respond differently to pharmacologic treatment 
(i.e., do women do more poorly)?
Several recent studies have clariﬁed that there are no gender differences 
in response to the major pharmacologic treatments for smoking cessa-
tion, nicotine replacement and bupropion. Shiffman et al11 conducted 
a secondary analysis of 2 RCTs, which used 21 mg nicotine patch and 
2- and 4-mg nicotine lozenge; outcomes were 6 month continuous 
abstinence and survival analysis. Active NRT was more effective than 
placebo among women for both patch and lozenge. In the lozenge trial, 
women were less successful than men, overall. The gender X treat-
ment interaction was not signiﬁcant in either study, so there was no 
evidence of differential treatment efﬁcacy by gender. In the lozenge 
trial, gender moderated the effects of smoking rate and dependence 
(but not treatment) on outcome; thus, more dependent women smokers 
had lower quit rates. Dependence predicted failure among women, but 
not men. In another study, Scharf and Shiffman12 examined gender 
differences in smoking cessation with and without bupropion, using 
pooled- and metanalyses of clinical trials of bupropion (4421 partici-
pants in 12 RCTs). Bupropion was an effective smoking cessation aid 
for women and there was no treatment X gender interaction; women 
and men beneﬁtted equally. However, women were less successful at 
quitting, overall. Thus, pharmacotherapy appears to be equally effective 
for women and men, but lingering questions remain about the overall 
success rates of cessation. 
IV. Future Research Needs
There is much to be learned about the biobehavioral basis of smoking 
and cessation, particularly in the areas of genetic determinants, nicotine 
dependence, affect, and the role of hormonal or other physiological fac-
tors. Basic behavioral aspects of smoking in women are also in need of 
further exploration, especially the role of sensory cues, and interperson-
al factors such as the need and type of support during cessation. Thus, 
the beneﬁts of tailoring for cessation treatment and relapse prevention 
have been hypothesized but not yet established. The literature suggests 
the existence of complex interactions among gender, biological and 
social variables, and cessation treatment.11 Cessation interventions at 
“teachable moments” in the (female) life cycle merit more research, 
such as pregnancy and child-rearing. These also include the impact of 
major illness (CVD, cancer, diabetes) in women, or childhood illnesses 
such as respiratory infections and asthma that promote parental cessa-
tion to reduce second hand smoke exposure. A major area for further re-
search is women’s tobacco use in the developing world: why do women 
begin to smoke and how to best help them stop; protecting nonsmoking 
norms while balancing social emancipation and ﬁnancial independence; 
and the inﬂuence of policy and economic issues. Many of these future 
research needs were set down in a major conference document.13 This 
is an exciting area and complex topic, and one deserving of a substan-
tial effort in research and public education.
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Introduction: Non small cell lung carcinoma (NSCLC) is a non-immu-
nogenic cancer. Unlike in melanomas, tumor inﬁltrating lymphocytes 
of the effector cell phenotype are not present in the tumor. NSCLC 
tumor cells thus have never been exposed to effector cells and, unlike 
melanoma, have not been selected to resist cytotoxic T lymphocyte 
(CTL) attack. Would NSCLC tumors be able to resist CTL, if CTL are 
generated by vaccination?
We designed two types allogeneic, whole cell NSCLC vaccines, gener-
ated from an NSCLC cell line (AD100) established in Miami and con-
ditioned to continuous growth in standard cell culture media. Genomic 
analysis of the morphological types of NSCLC, including squameous 
carcinoma, show largely overlapping genetic up- and downregulation 
of several hundred genes in the different cell types (1).
The B7- vaccine: The AD100 cell line was cotransfected with CD80 
(B7.1) and HLA A1 to render the cells immunogenic. Cells are irradi-
ated to prevent replication, but remain alive for several days when 
placed in culture. The in vivo immunogenicity of the vaccine is based 
on B7.1 expression which stimulates NK cell activation. 
Allogenicity and HLA A1 expression prevents engagement of killer 
inhibitory receptors (KIR) and inhibition of NK mediated cytotoxity. 
NK activation and killing of vaccine cells produces IFN- γ and releases 
tumor antigens. Dendritic cells and macrophages are attracted and take 
up released tumor antigens and cross present them to CD8 T cells dif-
ferentiating into CTL.
In a phase I study 19 patients were enrolled with stage IIIB/IV NSCLC 
who had failed several lines of prior therapy. They were treated by 
intracutaneous injection of 5x107 AD100-HLAA-B7.1 cells every 
two weeks for a maximum of nine vaccinations. The vaccine was safe 
causing no vaccine related serious adverse event. The immune response 
was measured by analyzing puriﬁed CD8 cells stimulated in vitro 
with vaccine cells for IFN-γ production by Elispot assays. All but one 
patient had a signiﬁcant immune responses. The mean response after 
three vaccinations was the generation of 160 NSCLC speciﬁc CD8 
CTL per ml of blood from a pre-immunization level of 0-1 CTL/ml. 
After 6 and 9 vaccinations the NSCLC speciﬁc CTL level increased to 
220 CTL/ml. One year survival was 47%, two year survival 32%. Six 
patients had a clinical response, rated as stable disease in 5 patients and 
a minor response in one.
Although uncontrolled the study showed a deﬁnite trend towards clini-
cal beneﬁt of B7 vaccination. We are currently conducting two phase II 
studies to determine effectiveness and to study the clinical response in 
patients with undetectable disease after surgery and chemotherapy.
The gp96-vaccine: Gp96 is the one of the major protein and peptide 
chaperones of the endoplasmatic reticulum. It transports peptides on 
their way to MHC class I presentation and helps folding of membrane 
associated and secreted proteins during synthesis. Srivastava was the 
ﬁrst (2)to show that gp96 isolated from tumor cells and injected into 
syngeneic mice was able to induce a tumor speciﬁc immune response 
that was able to protect mice from a subsequent challenge with the 
same tumor but not against other tumors. Gp96 is taken up by dendritic 
cells and macrophages via its endocytic receptor CD91 and causes acti-
vation of DC, independent of CD4 help and CD40-L/CD40 interaction. 
Uptake of gp96 and its chaperoned peptides results in cross presen-
tation of the peptides by MHC I of the DC and priming of antigen 
speciﬁc cognate CD8 T cells.
To render gp96 suitable for a vaccine system with allogeneic cells, we 
genetically modiﬁed the protein by deleting its endoplasmatic reticulum 
retention signal and replacing it with the Fc portion of IgG1 (3). Gp96-
Ig transfected tumor cells secrete gp96-Ig along with its chaperoned 
peptides. Injection of gp96-Ig transfected tumor cells into syngeneic 
mice results in tumor rejection associated with the clonal expansion of 
cognate CD8-CTL to a frequency of 15-40 of all CD8 cells (4). Clonal 
CD8 CTL expansion is enhanced in CD4 deﬁcient mice while CD40-L 
